Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Capell

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Journal of Thrombosis and Haemostasis : JTH|February 16, 2022
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy aloneScott D Berkowitz, Rupert M Bauersachs, Michael Szarek, et al.
Journal of the American College of Cardiology|April 24, 2024
Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and AtherosclerosisMarc P Bonaca, Deepak L Bhatt, Tabassome Simon, et al.
Circulation|November 3, 2020
Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and SafetyWilliam R Hiatt, Marc P Bonaca, Manesh R Patel, et al.
JAMA Network Open|June 22, 2022
Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity RevascularizationConnie N Hess, Michael Szarek, Sonia S Anand, et al.
European Heart Journal|August 25, 2021
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trialMori J Krantz, Sebastian E Debus, Judith Hsia, et al.
Journal of the American College of Cardiology|October 29, 2021
Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PADConnie N Hess, Manesh R Patel, Rupert M Bauersachs, et al.
Circulation|October 12, 2021
Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PADConnie N Hess, E Sebastian Debus, Mark R Nehler, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 29, 2023
Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 TrialConnie N Hess, Judith Hsia, Ian A Carroll, et al.
The New England Journal of Medicine|March 30, 2020
Rivaroxaban in Peripheral Artery Disease after RevascularizationMarc P Bonaca, Rupert M Bauersachs, Sonia S Anand, et al.
Journal of Vascular Surgery|December 5, 2022
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduitsNicholas Govsyeyev, Mark Nehler, Michael S Conte, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Journal of Thrombosis and Haemostasis : JTH|February 16, 2022
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy aloneScott D Berkowitz, Rupert M Bauersachs, Michael Szarek, et al.
Journal of the American College of Cardiology|April 24, 2024
Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and AtherosclerosisMarc P Bonaca, Deepak L Bhatt, Tabassome Simon, et al.
Circulation|November 3, 2020
Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and SafetyWilliam R Hiatt, Marc P Bonaca, Manesh R Patel, et al.
JAMA Network Open|June 22, 2022
Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity RevascularizationConnie N Hess, Michael Szarek, Sonia S Anand, et al.
European Heart Journal|August 25, 2021
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trialMori J Krantz, Sebastian E Debus, Judith Hsia, et al.
Journal of the American College of Cardiology|October 29, 2021
Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PADConnie N Hess, Manesh R Patel, Rupert M Bauersachs, et al.
Circulation|October 12, 2021
Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PADConnie N Hess, E Sebastian Debus, Mark R Nehler, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 29, 2023
Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 TrialConnie N Hess, Judith Hsia, Ian A Carroll, et al.
The New England Journal of Medicine|March 30, 2020
Rivaroxaban in Peripheral Artery Disease after RevascularizationMarc P Bonaca, Rupert M Bauersachs, Sonia S Anand, et al.
Journal of Vascular Surgery|December 5, 2022
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduitsNicholas Govsyeyev, Mark Nehler, Michael S Conte, et al.
Pageof 8